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Summary and Key Points 
1. Cancer is caused by mutations in the DNA of normal cells. Most 
cancers arise from cells that acquire somatic mutations over the 
course of years. Less commonly, some inherited germline mutations, 
present in all cells, can predispose cells to develop a cancer 
phenotype. 
2. Some DNA mutations that contribute to the formation of cancer arise 
in normal genes known as proto-oncogenes. Proto-oncogenes 
usually play key roles in the control of normal cell growth and 
division. 
3. Mutated proto-oncogenes that cause cancer are known as 
oncogenes. 
4. Tumor suppressor genes also normally function to control growth. 
When a cell's tumor suppressor gene is inactivated or lost, there is 
an increased probability of the cell proliferating and developing into a 
cancer. 
5. Division of cells with DNA mutations results in identical cancer cells 
(or a clone). Cancers can acquire additional mutations over time to 
develop multiple subclones which contribute to variability in a 
cancer's response to drugs and behavior (i.e. ability to metastasize). 
6. Metastasis is a multi-step process requiring cell separation from 
neighboring cells, infiltration through the basement membrane, 
entrance into blood vessels or lymphatics and tumor angiogenesis. 
Introduction 
Cancer cells arise from normal cells. Given that all our cells have the 
same genotype; it is reasonable to wonder what changes are needed to 
make normal cells become cancer cells. The answer appears to be that 
most cancers arise as the result of multiple somatic mutations to DNA. 
This chapter will focus on DNA mutations that cause cancer, abnormal 
regulation of cell growth and death, and metastasis. 
Carcinogenesis 
Most cancers occur only after a cell has acquired many mutations to 
create chromosomal instability. As a cell acquires mutations, it 
undergoes a variety of changes. There is a continuum from a perfectly 
normal cell to a cancer cell. Along this continuum, cells often change 
their appearance and behavior, a phenomenon known as dysplasia, 
before they become malignant. Although dysplastic cells appear quite 
different from normal cells, they are NOT cancer cells, and will not 
invade tissue or metastasize to other organs. Dysplastic cells may never 
progress to become cancer at all. However, if dysplastic cells acquire 
additional mutations, they may become frankly malignant. 
While mutations in DNA are a fundamental cause of cancer, other 
causes exist as well. Epigenetic changes affect both DNA and 
associated chromatin, without affecting the nucleotide sequence, and 
contribute to carcinogenesis by influencing gene expression. The classic 
example of an epigenetic change is methylation or demethylation of DNA 
to control cell division. Methylation of promoter regions of genes blocks 
transcription and silences the gene. If a gene promoter region is 
demethylated, the gene may be inappropriately transcribed. 
In general, the transformation of a normal cell into a cancer cell requires 
disruption of a variety of genes. However, there may instances where 
abnormal expression or function of a single gene may be sufficient to 
give rise to a malignancy. The translocation between chromosomes 9 
and 22 (t(9;22)(q34;q11.2)), also called the “Philadelphia chromosome”, 
results in a bcr-abl fusion gene which is diagnostic of and seems to be 
sufficient for the development of chronic myeloid leukemia (CML). 
However, additional mutations can and do occur in CML cells and these 
mutations can contribute to progression of disease to the rapidly lethal 
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“accelerated phase” and “blast phase” forms of the disease. The 
additional mutations can also cause resistance to the drug imatinib, 
which targets the tyrosine kinase function of the inappropriately 
expressed ABL. While the Philadelphia chromosome can also been seen 
in acute lymphocytic leukemia (ALL), the clinical course of ALL is 
different from CML. Ultimately; the form of a malignancy depends on all 
of the specific DNA mutations found in the cancer cell. Increasingly, 
clinicians utilize molecular studies to screen cancers for the presence of 
specific mutations. In many instances mutation analysis of cancers can 
lead to selection of specific treatments and provide information regarding 
prognosis of a cancer. 
Genes Involved in Cancer 
Oncogenes 
It is not surprising that many mutations found in cancer occur in genes 
responsible for cell division and growth. One such class of genes is 
termed proto-oncogenes. Proto-oncogenes are essential to growth and 
mitosis in a normal cell. However, mutations in proto-oncogenes give rise 
to oncogenes, which contribute to the formation of cancer cells. 
It is useful to keep in mind the following four functional categories of 
proto-oncogenes. These include: 
1. Growth factors- protein hormones secreted by cells to stimulate 
growth of other cells 
2. Growth factor receptors 
3. Transcription factors- proteins that bind to gene promoter regions 
and control gene transcription 
4. Genes that regulate the synthesis of a number of proteins involved 
in intracellular signaling 
A partial list of proto-oncogenes and their normal cell function is provided 
in Table 1. 
 
 
 
 
 
 
Table 1. Proto-Oncogenes 
Proto-Oncogene Type Comment 
Growth Factor  
Sis Platelet-Derived Growth Factor 
Growth Factor Receptor  
erbB Epidermal Growth Factor Receptor 
(EGFR) 
neu (erb-2/her-2) Member of EGFR Family 
Intracellular Signaling  
Src Tyrosine Kinase: Animal Homolog is 
Rous Avian Sarcoma 
Raf Serine/Threonine Kinase 
K-ras GTPase Activity 
Nuclear Transcription Factors  
Jun  
Myc  
The epidermal growth factor receptor (EGFR) gene family is an example 
of proto-oncogenes. These genes code for membrane receptors and 
also have tyrosine kinases which normally regulate signal transduction 
for cell proliferation, survival, adhesion, migration, and differentiation. 
The family includes four transmembrane receptors which include EGFR 
(erb-1), Her2 (also known as neu, erb-2, Her2/neu), HER3 (erb-3), and 
Her4 (erbB-4). While each receptor can be activated by a ligand, Her2 is 
activated through heterodimerization with the other erb tyrosine kinases. 
Mutations can lead to constitutive (or constant) activation and promote 
carcinogenesis. The presence of these mutations can be tested. For 
example, Her2 testing is commonly performed in breast and gastric 
cancers. The presence of Her2 mutations allows for treatment with drugs 
such as trastuzumab, a monoclonal antibody directed against the Her2 
receptor. 
Another classic proto-oncogene is B-raf (or BRAF). BRAF is involved in 
the intracellular signal transduction of the MAPK pathway, which is a key 
pathway that can lead to mitosis. Mutations within this pathway lead to a 
number of cancers including melanoma, thyroid cancer, and colorectal 
cancers. For example, in melanoma the most common BRAF mutation is 
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a nucleotide substitution, leading to expression of a different amino acid 
at codon 600 (V600E). This mutation site is present in 50% of 
melanomas. Testing of melanoma for the presence of BRAF mutations 
permits the use of drugs such as vemurafinib or dabrafenib, which inhibit 
BRAF which possess the V600E mutation. 
Tumor Suppressor Genes 
Tumor suppressor genes represent another common class of genes 
frequently altered in cancers. Tumor suppressor genes encode proteins 
which downregulate cell proliferation and control cell cycle checkpoints 
necessary for cell growth. Tumor cells commonly exhibit mutations in 
tumor suppressor genes such as Rb and p53. 
Rb is a nuclear phosphoprotein which regulates the cell cycle at the 
G1/S checkpoint. When hypophosphorylated, Rb binds E2F, blocking 
entry into S phase. In its hyperphosphorylated state, Rb releases E2F 
permitting entry into S phase. A germline mutation in Rb is associated 
with retinoblastoma. 
P53, on chromosomal locus 17p13.1, is known as the gate keeper of the 
cell cycle. P53 is a transcription factor which regulates hundreds of 
genes and prevents proliferation of cells with DNA damage or shortened 
telomeres. For example, activated p53 upregulates the mir34 family of 
microRNAs which inhibits translation of growth promoting genes (such as 
CDK4, MyC and anti-apoptosis genes such as BCL-2) to act as a pro-
apoptotic protein. P53 acts to produce a temporary or permanent cell 
cycle arrest or to direct cells into the apoptotic pathway. 
Mutations in P53 are some of the most common genetic alterations in 
cancer. The function of p53 is abrogated by an acquired somatic 
mutation of both alleles. Mutations of p53 are usually present in its DNA 
binding domain. More than 50% of malignancies have a p53 mutation, 
including many of the most common tumors (i.e. breast, colon and lung 
cancer). 
In fact, most cancers show a defect in one or more of the crucial proteins 
involved in control of the cell cycle. Some of the proteins commonly 
affected include Rb, cyclin D1, CDK4, and p16INK. 
Abnormalities in the apoptotic pathways allow a cancer cell to circumvent 
cell death. Indeed, most cancer cells are potentially immortal – if 
provided with constant nutrition and removal of waste products. The 
immortality of cancer cells was first exploited to develop tissue culture 
cell lines in which multiple generations or passages of cells can be 
maintained for decades, whereas normal cell enter apoptosis after 60-70 
doublings. 
This potential immortality of cancer cells is in part due to preservation of 
telomeres. Telomeres are a series of short tandem nucleotide repeats 
that are present at chromosomal ends. As normal cells replicate, their 
telomeres shorten. Eventually cells with short telomeres undergo cell 
cycle arrest mediated by the Rb and p53 pathways. The enzyme 
telomerase maintains telomere length, and is active in stem cells and 
cancer cells. This confers unlimited growth potential. 
DNA Repair Genes 
DNA mutations can occur with remarkable frequency in the life of a cell 
through errors introduced during replication. A variety of DNA repair 
enzymes exist to remove and fix these mutations. Loss of DNA repair 
enzymes leads to an increased risk of permanent DNA damage with 
consequences including progression to cancer. A number of inherited 
syndromes that lead to an increased risk of cancer are due to loss of 
DNA repair enzymes. Examples include deleterious mutations in BRCA1 
or BRCA2 and in any of the genes responsible for the hereditary non-
polyposis colon cancer syndrome (HNPCC, also known as Lynch 
Syndrome). In all of these examples, the affected gene encodes a DNA 
repair enzyme. Loss of function of that enzyme increases genetic 
instability in affected cells, leading to carcinogenesis. 
microRNA 
MicroRNA is single stranded RNA of 18-25 nucleotides in length. First 
identified in the early 1990’s, it has become increasingly clear in the last 
two decades that microRNAs control a variety of critical cellular 
functions. Over 2000 microRNAs have been identified in human cells. 
They are synthesized and processed in the nucleus and then transit to 
the cytoplasm where they bind specific mRNAs, leading to interruption of 
translation and destruction of mRNA. 
The expression and function of miRNAs is cell specific and miRNAs can 
act as both “oncogenes” and “tumor suppressor genes”. For example, 
miR-21 is overexpressed in a variety of malignancies and this leads to 
inhibition of negative regulators of the RAS/MEK/ERK pathway, resulting 
in cell proliferation and inhibition of apoptosis. By contrast, miR-34 
Cancer Biology 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (8 March 2016) 
4 
expression induces apoptosis and downregulation of miR-34 in cancer 
cell lines leads to cancer cell proliferation. 
MicroRNAs can be found circulating in blood or shed into sputum or 
feces. Measurement of miRNAs has been proposed for screening for 
cancers and as a way to gain prognostic information in patients 
diagnosed with cancer. 
Cancer Stem Cells 
It is thought that cancers possess a population of stem cells sufficient to 
propagate a tumor. These cancer stem cells need not arise from a pool 
of normal stem cells. Rather, somatic mutations may result in a 
differentiated cell reverting to a stem cell phenotype.  If this hypothesis is 
correct, true eradication of cancers would require therapy targeting the 
stem cell population. Cancer stem cells likely comprise less than 1%-
25% of a tumor population but may be resistant to conventional 
chemotherapy. 
Cancer Genetics 
Cancer cells are prone to acquire additional mutations. It is therefore 
common for cancers to have multiple sub-clones of the original malignant 
cell. These new clones possess different metastatic abilities or develop 
resistance to different chemotherapeutic drugs. The presence of clonal 
variation within cancers explains the frequently observed phenomenon of 
cancers initially shrinking in response to chemotherapy, but subsequently 
growing back. Presumably, the recurrent cancer cells are derived from 
clones selected out from the bulk of tumor by their resistance to 
chemotherapy. This phenomenon has also been referred to as tumor cell 
heterogeneity, a term that stresses the variability that can exist between 
cancer cells within the same tumor. 
Inherited Cancer Syndromes 
This discussion of carcinogenesis has emphasized that cancers arise 
through acquired mutations. However, rare inherited cancer syndromes 
do exist and have informed our understanding of carcinogenesis. The 
syndromes listed below (Table 2) are inherited in autosomal dominant 
fashion. 
 
Table 2. Inherited Cancer Syndromes 
Mutation Syndrome 
RB Retinoblastoma 
P53 Li-Fraumeni Syndrome (multiple 
cancers) 
APC Familial adenomatous polyposis 
(colon) 
MLH1, MSH2, MSH6, PMS2 Lynch Syndrome (colon, ovary) 
BRCA1, BRCA2 Breast, Ovary 
These syndromes involve an inherited mutation in a single allele of a 
tumor suppressor gene. Loss or inactivation of a single allele is clinically 
silent. The acquisition of a mutation in the second normal allele results in 
complete loss of function of the gene and markedly increases the 
probability of cancer development. This phenomenon has been referred 
to as “loss of heterozygosity” because individuals with these syndromes 
are genotypically heterozygous for the normal gene and its mutated 
counterpart. 
Cancer Cell Kinetics 
Cancer growth rates vary greatly. Highly aggressive lymphomas or 
leukemias may double every 24 hours. Many cancers that arise from 
solid organs, however, may have doubling times of many months. Within 
the same cancer, growth rates may change as the cancer expands, 
possibly through the emergence of clones with varying rates of growth. 
Doubling times of cancer have important clinical implications. A tumor 
with a diameter of about a centimeter has roughly one billion (109) cells. 
Assuming constant doubling of the original cancer cell with no loss of 
cells during tumor growth, this represents roughly 30 cell doublings 
(230≈109). As noted above, many cancers may have doubling times of 
several months or more. This implies that formation of a tumor with a 1 
cm diameter – probably the smallest size that a nodule can be reliably 
found on chest x-ray – may take three to ten years from the initiation of 
the original cancer cell in the tumor. This also means that growth of 
many cancers will proceed for years before the cancer reaches a size 
that is clinically detectable. 
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Metastases 
Metastases are the hallmark of a malignant tumor. They represent 
spread of tumor cells away from the primary tumor. Fortunately, the 
development of metastases presents a hurdle for many cancers. It is 
thought that while millions of cancer cells are shed into the circulation 
daily, few (<0.01%) are able to initiate tumor growth at a distant site. For 
most malignancies, metastases are responsible for death. 
Normal cells typically adhere to their neighboring cells and the 
surrounding extra-cellular matrix. A variety of protein families, including 
integrins, cadhedrins, selectins, and other cell adhesion molecules 
(CAMs) anchor cells to one another. Mutations in CAMs are frequently 
present in cancer cells. These mutations make it easier for cancer cells 
to disaggregate from one another in order to spread out beyond the 
normal cell’s usual anatomic boundary. 
In order to metastasize, a cell or group of cells must detach from the 
primary tumor, digest and move through the intercellular matrix and 
penetrate the vascular basement membrane. Enzymes, like matrix 
metalloproteinases are upregulated in cancer cells to facilitate this 
process. 
Once in the circulatory system, the cells must escape the immune and 
coagulation systems. Cancers must then must lodge in a distant capillary 
or venule and again travel through the vascular wall, lodge in the 
extracellular matrix and grow. 
As soon as cancer cells have moved to a new location, their growth will 
be limited unless they can establish a blood supply. Diffusion of oxygen 
and nutrients into a collection of cells only permits growth of spherical 
colonies smaller than a few hundred microns. Larger growth requires the 
formation of new tumoral blood vessels. Successful cancers can 
elaborate growth factors such as vascular endothelial growth factor to 
stimulate angiogenesis (new blood vessel growth). Few cells succeed in 
this series of steps required for metastasis, but as so many cells attempt 
this journey, metastasis is common for many tumors. 
Tumor metastasis is not a random process. Certain tumors have a 
propensity to metastasize to specific sites. Some tumor spread is related 
to normal anatomy. For example, the liver is the most common site of 
metastatic spread for colorectal cancers. Invasion into the portal 
vasculature results in the liver being the first organ that metastasizing 
colorectal cancer cells enter. However, many common sites of 
metastases are not so easily explained. For example, prostate and 
breast cancers tend to spread to bones while lung cancers preferentially 
spread to the adrenal glands. In these instances, it is likely that local 
growth factors within tissues provide a receptive “soil” for the metastatic 
“seed” to grow. 
Conclusion 
Cancers arise from normal cells as the result of mutations in critical 
genes. These mutations are usually acquired during life but, less 
commonly, can also be inherited. Cancers are characterized by poorly 
regulated cell growth and the ability to metastasize. The mutations that 
give rise to cancers are passed down to successive generations of 
cancer cells. However, individual cells within a cancer can acquire their 
own new mutations that may result in subclones with different properties 
than the rest of the tumor. 
Understanding the biology underlying the development, growth, and 
spread of cancers is critical if one hopes to develop treatments that 
target cancer cells. Once cancer cells have moved to a new location, 
their growth is limited unless they can establish a blood supply. Diffusion 
of oxygen and nutrients into a collection of cells permit growth of 
spherical colonies to diameters of a few hundred micrometers. Larger 
growth requires only blood vessels. Tumors are capable of elaborating 
growth factors such as vascular endothelial growth factor to stimulate 
new blood vessel growth. 
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Thought Questions 
1. With increasing exposure to carcinogens on a daily basis and longer 
survival rates, what prevents everyone from getting cancer? 
Your answer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. If an invasive tumor is capable of generating many circulating tumor 
cells, why might only a few succeed in becoming metastatic 
cancers? Why do cancers have preferred metastatic sites? 
Your answer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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Glossary 
Apoptosis- Programmed cell death; a normal process of cell death that is 
triggered by a variety of factors, including sometimes as a part of normal 
cell development. 
Dysplasia- Abnormal cell appearance and behavior 
Matrix metalloproteinases- Enzymes that catalyze the hydrolysis of 
extracellular matrix proteins. These enzymes typically contain a zinc 
atom in their catalytic domain. 
Oncogene- Product of a mutation in an oncogene.  This leads to their 
constitutive activation which allows cells to grow without normal control 
mechanisms. 
Proto-oncogene- Normal cellular counterpart of an oncogene 
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